Breast carcinoma

This study tests a personalized cancer vaccine (ABO2109) combined with an immunotherapy drug (toripalimab) in 50 adults with solid tumors. The goal is to see if the vaccine is safe and triggers an immune response against the cancer. Participants must have good organ function and …

This trial is testing a new drug called DS1025a in people with advanced solid tumors that have spread, cannot be removed by surgery, or have stopped responding to other treatments. The main goals are to check the drug's safety, how the body processes it, and whether it shows any …

This study tests a combination of three drugs—tislelizumab, bevacizumab, and capecitabine—in people with advanced solid tumors. The trial focuses on two challenging groups: those whose cancers have stopped responding to immunotherapy and those with tumors that have spread to the …

This trial provides continued access to three experimental Bicycle therapies—zelenectide pevedotin, nuzefatide pevedotin, and BT7480—for people with advanced solid tumors who are already benefiting from them in another study. Participants continue their same treatment while resea…

This study provides continued access to alpelisib for people who are already benefiting from it in a previous Novartis trial. It focuses on tracking long-term safety, including any side effects, in participants with PIK3CA-related overgrowth spectrum or certain breast cancers. Pa…

This early-stage trial tests a new drug called SI-B036, a bispecific antibody designed to fight advanced gastrointestinal and other solid tumors. The study involves about 16 adults with tumors that have spread or cannot be removed. Researchers aim to find a safe dose and see if t…

This Phase 3 trial tests whether a combination of two drugs, trastuzumab rezetecan and adebrelimab, can prevent breast cancer from returning in people with triple negative breast cancer who still have cancer cells after initial chemotherapy and surgery. The study compares this ne…

This study tests an experimental oral drug called GFH276 combined with either cetuximab or standard chemotherapy in people with advanced solid tumors or pancreatic ductal adenocarcinoma (PDAC) that have a RAS mutation. The goal is to see if the combination is safe, tolerable, and…

This phase 2 trial investigates whether tirzepatide, a drug used for weight loss and diabetes, can slow tumor growth in people with early-stage hormone-receptor-positive breast cancer. Participants receive tirzepatide alone, the standard hormone therapy letrozole alone, or both t…

This study investigates cryoablation, a procedure that freezes and destroys tumor tissue, for treating the primary breast tumor in women with metastatic breast cancer. The goal is to see if this minimally invasive approach can control the local tumor for 12 months while patients …

This early-stage trial tests a new drug called SHR-4685 in people with advanced solid tumors that have not responded to other treatments. The main goals are to check the drug's safety, find the best dose, and see how the body processes it. About 170 adults aged 18 to 75 with meas…

This pilot study tests whether adding a device called TheraBionic P1 to standard treatment can help women with metastatic triple negative breast cancer who have already tried two prior treatments. The device delivers low-level radiofrequency electromagnetic fields and is used alo…

This early-phase trial is testing whether two experimental drugs, SCTB41 and SCTB39G, given together every three weeks, are safe and can shrink tumors in adults with advanced solid tumors that have not responded to standard treatments. The study will enroll 112 participants acros…

This study tests a new biologic drug called XYA02 in 190 adults with advanced solid tumors (including lung, ovarian, and pancreatic cancers) that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug can shrink tumo…

This phase 3 trial is testing a drug called trastuzumab rezetecan, alone or combined with bevacizumab, in 140 women with advanced triple-negative breast cancer that has a specific immune-suppressed pattern. The goal is to see if the combination can delay cancer growth better than…

This early-phase trial tests an oral drug called Zn-Telomir in 76 adults with advanced or metastatic triple-negative breast cancer that has worsened after prior treatments. The study has two parts: first, finding a safe dose, and second, checking if the drug shrinks tumors. It is…

This phase 3 trial is testing a daily pill called giredestrant in 300 people with ER+/HER2- early breast cancer who had to stop standard aromatase inhibitors due to side effects. The study will track how well patients stick with the treatment, their quality of life, and any side …

This extension trial follows patients with advanced solid tumors who are already receiving or have received gotistobart in earlier studies. The goal is to assess long-term safety and overall survival over an extended period. Participants must be 18 or older and have been part of …

This Phase 1 trial tests D3L-002, a new drug that targets two immune checkpoints (TIGIT and PVRIG) to help the immune system fight cancer. It is for 24 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the r…

This Phase II trial will test whether adding a live biotherapeutic product called MO-03 (a type of probiotic) to standard chemotherapy and the immunotherapy drug pembrolizumab can improve outcomes for 50 people with early-stage triple-negative breast cancer. Participants will tak…

This early-stage trial is testing a new cell therapy called GK01 in 10 people with advanced solid tumors that have stopped responding to standard treatments. The therapy uses the patient's own immune cells (T cells) that are trained to attack the tumor. The main goal is to check …

This study tests a new drug called LM-168 combined with other cancer treatments (tislelizumab or docetaxel) in 108 adults with advanced solid tumors. The first part finds a safe dose; the second part checks if the combination shrinks tumors. It is not yet recruiting.

This study is testing whether some people with early-stage breast cancer can safely skip surgery after chemotherapy and instead use only radiation. It includes 84 adults with HER2-positive or triple-negative breast cancer who have responded well to initial chemo. The goal is to s…

This study tests whether adjusting common over-the-counter medications can make immune checkpoint inhibitors work better for people with solid tumors. Participants are asked to avoid acetaminophen and cannabis/THC/CBD, while taking aspirin and loratadine (or similar antihistamine…

This early-stage trial tests LNF2105, a drug designed to target and deliver a toxin to cancer cells that have a protein called Nectin-4 on their surface. It will enroll about 294 adults with advanced solid tumors (such as bladder, breast, or lung cancer) who have run out of stand…

This early-stage trial tests a new approach to CAR-T therapy where a virus is injected directly into the bloodstream to reprogram a patient's own immune cells to attack cancer. It involves 91 adults with advanced solid tumors who have run out of standard options. The main goal is…

The SASHA trial is testing whether a single, high-dose radiation treatment delivered directly to the tumor site over one day is safe and effective for women with early-stage breast cancer. The study will enroll 134 women aged 40-85 who have already had a lumpectomy. Researchers w…

This study tests a risk-based approach to radiation after breast-conserving surgery for early breast cancer. Depending on individual risk, patients receive either whole-breast or partial-breast radiation in fewer, larger doses (hypofractionation). The goal is to maintain cancer c…

This Phase 2 trial tests BL0175, a nano-medicine that delivers cancer-fighting drugs directly into tumors. It enrolls 120 postmenopausal women with HR+/HER2- advanced breast cancer. Researchers compare different doses to find the safest and most effective one for shrinking tumors…

This early-stage trial tests a new drug called CS5007 in people with advanced solid tumors that cannot be removed by surgery. The drug is designed to seek out and attack cancer cells while sparing healthy ones. The study will first find the safest dose and then check if the drug …

This phase 3 trial is testing two oral drugs, camizestrant and ribociclib, as a first treatment for people with ER-positive, HER2-negative advanced breast cancer. The goal is to see if the combination can delay the need for next cancer therapy. About 150 participants will take th…

This early-phase trial is testing whether a personalized cancer vaccine, made from a patient's own tumor, can safely boost the immune system's ability to fight triple negative breast cancer. About 30 newly diagnosed patients will receive the vaccine along with standard chemothera…

This early-stage trial is testing two experimental drugs, OVV-01 and AK112, in 30 people with advanced solid tumors that have not responded to standard treatments. OVV-01 is given both into a vein and directly into the tumor, while AK112 is given into a vein. The main goals are t…

This phase 3 trial compares an experimental drug called BL-B01D1 to standard chemotherapy in people with a common type of breast cancer (HR+/HER2-) that has stopped responding to hormone therapy and cannot be removed by surgery. The study aims to see if BL-B01D1 can delay cancer …

This early-phase trial tests an experimental drug called CLSP-5282 in up to 140 adults with advanced solid tumors (like lung, pancreatic, or colorectal cancer) that have a specific genetic change called KRas G12V. The drug is given by IV infusion. The main goals are to check safe…

This study tests whether adding an immune-boosting drug called eftilagimod alpha to standard chemotherapy before surgery can completely eliminate tumors in people with early-stage hormone receptor-positive, HER2-negative breast cancer. About 50 participants will receive the drug …

This Phase 1 trial tests MST-168, an antibody-drug conjugate designed to target and kill cancer cells. It will enroll 420 adults with advanced solid tumors that have specific markers. The main goals are to check safety, find the right dose, and see early signs of tumor shrinkage.

This phase II trial is testing a three-drug combination given before surgery for people with intermediate-to-high risk HR-positive, HER2-low breast cancer. Participants first take dalpiciclib (a pill) plus an aromatase inhibitor (another pill) for about 4 months, followed by infu…

This study tests a drug called SHR-A1811 in 60 adults with HER2-positive advanced breast cancer who have had up to 2 prior treatments. Researchers want to see if giving the drug in different ways (like injection or infusion) can shrink tumors. The main goal is to measure how many…

This phase 3 trial tests whether a combination of sacituzumab govitecan (Trodelvy) and pembrolizumab (Keytruda) works better than standard chemotherapy before surgery for stage II-III triple-negative breast cancer. About 765 participants will be enrolled. The study aims to improv…

This early-phase trial tests a new drug called YKYY031 in 76 people with advanced solid tumors (like colorectal or pancreatic cancer) that have stopped responding to standard treatments. The main goals are to check safety, find the right dose, and get a first look at whether the …

This study tests a new drug (GV20-0251) combined with an immunotherapy (anti-PD-1) in people with advanced solid tumors that have not responded to or cannot tolerate standard treatments. About 227 adults with various cancers, including lung, breast, and colorectal, will participa…

This study tests a drug called Trastuzumab Rezetecan in 15 adults with advanced solid tumors that have the HER2 protein. The goal is to see if the drug can shrink tumors. Participants get the drug by IV every 3 weeks. This is for people whose cancer has worsened after other treat…

This study tests a drug called ifinatamab deruxtecan (I-DXd) in children with solid tumors that have returned or not responded to treatment. The drug is an antibody-drug conjugate that targets cancer cells directly. The trial aims to check safety and see if tumors shrink in about…

This study tests whether a new drug, trastuzumab rezetecan, works as well as or better than the current drug trastuzumab deruxtecan for women with advanced HER2-positive breast cancer that has worsened after previous treatment. About 100 women will be randomly assigned to one of …

This early-stage study tests a new tablet called GW01-200 in 100 people with advanced solid tumors or blood cancers that have stopped responding to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. Participan…

This study looks at whether a structured support program can help people with early-stage, hormone-positive breast cancer stick to their ribociclib medication (taken with an aromatase inhibitor). About 90 participants will be split into two groups: one gets standard care, the oth…

This study tests whether a new drug, sacituzumab tirumotecan (Sac-TMT), followed by standard chemotherapy (capecitabine), works better than capecitabine alone to keep early-stage, high-risk triple-negative breast cancer from returning. About 420 women without BRCA gene mutations …

This phase 2 trial is testing a combination of three drugs—inavolisib, ribociclib, and fulvestrant—in 160 Chinese women with a specific genetic mutation (PIK3CA) in hormone receptor-positive, HER2-negative advanced breast cancer that has stopped responding to endocrine therapy. T…

This study tests a new drug called FG-B901, a bispecific antibody that targets two immune proteins (PD-L1 and CD40) to activate the immune system against tumors while reducing side effects. It is given alone or with chemotherapy to 264 adults with advanced solid tumors that have …

This early-stage study tests a new drug, JSKN021, in about 199 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety and find the best dose. Researchers will also look for signs that the drug shrinks tumors…

This early-stage study tests a new tablet, LT-010391, in people with advanced solid tumors (lung, colon, or pancreatic cancer) that have a specific genetic change called KRAS G12D. The main goals are to check safety and find the right dose. About 198 participants who have tried o…

This study tests a new drug called ICP-B208 in about 539 people with advanced solid tumors that cannot be removed by surgery or have spread. The main goals are to check the drug's safety, find the best dose, and see if it shrinks tumors. Participants must be 18-75, have failed pr…

This study tests a combination of two drugs, zongertinib and fulvestrant, in people with advanced breast cancer that is hormone receptor-positive and HER2-negative but has a specific HER2 gene mutation. The goal is to see if the combination shrinks tumors. About 25 adults will ta…

This study tests a new drug (SYS6006) combined with another drug (Enlonstobart) in people with advanced solid tumors that cannot be removed by surgery or have spread. The goal is to see if the combination is safe and works better than Enlonstobart alone. About 264 adults will tak…

This early-stage study tests a new drug called QLC5508 in 48 adults with advanced solid tumors that have stopped responding to treatment. The main goals are to check if the drug affects heart rhythm, compare two versions of the drug, and see how it interacts with other medicines.…

This study looks at whether women with triple-negative breast cancer who have a complete response to chemo-immunotherapy can safely skip breast and lymph node surgery. Half of the 150 participants will receive standard care including surgery, while the other half will have no sur…

This early-phase study tests a new treatment called CAR-DC for people with advanced solid tumors (like lung, liver, or stomach cancer) that have not responded to standard care. The therapy uses a patient's own immune cells, modified in a lab to recognize and attack cancer cells. …

This early-stage trial tests a new drug called Hemay5087 in 24 people with advanced solid tumors that have not responded to standard treatments or have no standard options. The main goals are to check safety, find the right dose, and get a first look at whether the drug can shrin…

This early-stage study tests a new drug called HH160 in about 56 adults with advanced solid tumors (cancers that have spread). The main goals are to check safety, find the best dose, and see if the drug shrinks tumors. Participants will receive HH160 alone or with other cancer tr…

This phase 2 trial tests a drug called BMS-986504 in people with advanced solid tumors that have lost a gene called MTAP. The drug is given alone or with other cancer medicines. The study aims to see if the drug shrinks tumors and how safe it is. About 260 adults will take part.

This early-phase trial tests a new drug called WSK-IM02 in 9 people with advanced solid tumors that have spread to cause fluid buildup around the lungs or in the belly. The drug is given directly into the chest or abdomen to see if it is safe and can shrink tumors or reduce fluid…

This early-phase trial tests a combination of two drugs, CVL006 and 9MW2821, in 108 adults with advanced solid tumors that have not responded to standard therapy. The goal is to find a safe dose and see if the combination can shrink tumors. The study is not yet recruiting.

This early-stage trial tests a new drug called CS231295 in 42 adults with advanced solid tumors that have stopped responding to standard treatments. The drug works by blocking certain proteins that help tumors grow and form blood vessels. The main goals are to check safety, find …

This Phase 2 trial will enroll 100 young women (ages 18-45) with hormone receptor-positive breast cancer who are already on a 3-month GnRH injection for ovarian suppression. Half will switch to a monthly injection, while the other half stays on the 3-month schedule. The study aim…

This early-phase study tests a new drug, BI 1831169, combined with an existing immunotherapy (nivolumab) in Japanese adults with advanced solid tumors that have spread or not responded to prior treatments. The main goal is to find a safe, tolerable dose. Up to 46 participants wil…

This phase III trial is for people with HER2-positive stage IV breast cancer that has spread to a limited number of spots (oligometastatic). It tests whether adding surgery and focused radiation to standard drug therapy helps them live longer or delays cancer growth compared to d…

This early-stage study tests a new drug called JL19001 in people with advanced solid tumors or a type of lymphoma that has come back or not responded to treatment. The main goal is to find a safe dose and check for side effects. About 14 participants will receive the drug as a sh…

This Phase 2 trial tests an oral form of the chemotherapy drug paclitaxel, taken daily or three times a week, for people with advanced HER2-negative breast cancer. The study first finds the best dose of the oral pill alone, then combines it with the immunotherapy toripalimab to s…

This study tests an experimental drug called IDP-001 in people with advanced or metastatic solid tumors, including certain lung, head and neck, and other cancers. The trial has two phases: first to check safety and find the right dose, then to see if the drug can shrink tumors. A…

This study tests whether a new biosimilar drug, HLX319, works as well as the approved drug Phesgo for people with HER2-positive early or locally advanced breast cancer. About 258 participants will receive either the biosimilar or the original drug before surgery to compare how th…

This early-stage trial tests a new drug called HF50 in 45 adults with advanced solid tumors that have not responded to standard treatments. HF50 is designed to target HER2 on cancer cells and boost the immune system. The main goals are to check safety, find the right dose, and se…

This study tests a new drug, prifetrastat, combined with fulvestrant for people with advanced HR+/HER2- breast cancer that has stopped responding to standard hormone therapy and CDK4/6 inhibitors. About 51 participants will receive the combination to see if it can shrink tumors o…

This study tests whether starting abemaciclib at a lower dose and gradually increasing it can reduce early side effects like diarrhea and fatigue in people with high-risk HR+/HER2- breast cancer. The goal is to help more patients stay on their full treatment plan. About 86 partic…

This early-phase study tests a new drug called IN10028 in 75 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug shrinks tumors when used alone or with other cancer drugs. Th…

This study will follow 500 people with advanced HER2-positive breast cancer who are receiving pyrotinib (a daily pill) as their first or second treatment. Researchers want to see how well the drug works in real life and whether switching to another targeted therapy (Trastuzumab R…

This study tests a program to help women with ER-positive breast cancer in Rwanda take their daily hormone therapy as prescribed. The program includes education, reminders, and behavioral support. Researchers will measure how well participants stick with their medication and how …

This study tests a drug called sparsentan to reduce high levels of protein in the urine (proteinuria) caused by certain cancer treatments. About 20 adults with cancer who are taking VEGF inhibitors and have developed proteinuria will receive sparsentan for 8 weeks. The goal is to…

This study tests two experimental drugs (SCTB41 and SCTB39-1) given together, sometimes with standard cancer therapy, in adults with advanced solid tumors that have not responded to prior treatments. The goal is to find safe doses and see if the combination can shrink tumors or s…

This study tests whether adding 4 cycles of the targeted drug trastuzumab rezetecan (T-DXh) can eliminate residual cancer in HER2-positive breast cancer patients who still have disease after standard chemotherapy. About 59 adults will receive the drug before surgery. The main goa…

This early-stage trial tests a new drug (non-cationic peptide-CD47 siRNA) in about 9 people with advanced solid tumors that have not responded to other treatments. The drug works by blocking a 'don't eat me' signal on cancer cells, helping the immune system recognize and attack t…

This early-stage trial tests a new drug called JH021 in 60 people with advanced solid tumors that have stopped responding to standard treatments. JH021 is a special antibody that targets two cancer-related proteins, EGFR and cMET, to potentially slow or stop tumor growth. The mai…

This early-phase trial tests a new mRNA-based immunotherapy called PMC2129G12 in 60 adults with advanced solid tumors that have not responded to standard treatments. The therapy is injected directly into tumors to help the body's immune T cells attack cancer cells. The main goals…

This study tests a combination of targeted drugs (trastuzumab and pertuzumab) plus a low-dose chemotherapy (vinorelbine) given before surgery to elderly patients (70+) with HER2-positive breast cancer. The goal is to see if this approach can completely eliminate cancer cells in t…

This study tests two experimental drugs, AK146D1 and AK112, given together to people with advanced breast cancer that has spread or come back. The goal is to see if the combination is safe and can shrink tumors or slow the disease. About 200 adults aged 18 to 75 with HER2-negativ…

This study tests a new drug called SKB118 in 332 adults with advanced solid tumors that have not responded to standard treatments. The drug is given by IV every three weeks. The trial will first find the safest dose, then check if it can shrink tumors. It is currently not recruit…

This early-phase study tests a new mRNA-based treatment for people with advanced solid tumors that have not responded to standard therapies. The treatment aims to control tumor growth by delivering a specific protein (IL-22BP) using a peptide carrier. The main goals are to check …

This early-phase trial tests a radioactive drug called tin-117m-DTPA in 24 people with prostate, breast, or lung cancer that has spread to the bones. The drug is designed to deliver low-level radiation directly to bone tumors while being gentler on the bone marrow. Researchers wi…

This trial looks at whether children with cancer who develop a fever and low white blood cells can safely stop antibiotics earlier than usual. About 136 children will be randomly assigned to either stop antibiotics within 24 hours or continue standard treatment. The goal is to se…

This early-phase trial tests a new drug called SYS6051 in 114 adults with advanced solid tumors that have not responded to standard treatments. The study aims to find a safe dose and check for early signs of tumor shrinkage. Participants receive the drug by IV every three weeks.

This early-phase study tests a new mRNA medicine (NCP-IL-22BP mRNA) in 9 people with advanced solid tumors that have not responded to standard treatments. The medicine is injected directly into tumors to help the body fight cancer. The main goal is to check safety and find the ri…

This Phase 2 trial tests a new combination of drugs—paclitaxel polymer micelles, trastuzumab, pertuzumab, and adebelimab—against the standard taxane-based regimen for people with advanced HER2-positive breast cancer. About 140 participants will be randomly assigned to one of the …

This study tests an experimental drug called SKB565 in 180 adults with advanced solid tumors that have not responded to or cannot tolerate standard treatments. The trial has three stages to find the safest dose, check how the drug moves through the body, and see if it shrinks tum…

This study tests a new combination of drugs (PLD, cyclophosphamide, trastuzumab, and pertuzumab) for people with HER2-positive early breast cancer who still have cancer after initial treatment. The goal is to see if this combo can increase the rate of complete remission before su…

This early-stage trial tests a new drug called AK150 in about 96 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and find the right dose. Researchers will also look for signs that the drug shrinks tumors.

This study tests a new drug, asciminib, combined with trastuzumab in 42 adults with HER2+ breast cancer that has spread to the brain. Participants must have tried at least one prior treatment, including T-DXd and tucatinib. The goal is to see if the combination can shrink brain t…

This study looks at envafolimab, a cancer drug given as a quick shot under the skin instead of a long IV drip. It is for adults with advanced solid tumors who have not responded to standard treatments. The goal is to see how well it controls tumors and what side effects occur in …

This phase 3 trial compares a new drug called 9MW2821 to standard chemotherapy in 356 people with advanced triple-negative breast cancer who have already received certain prior treatments. The main goal is to see if the new drug helps people live longer. Participants will receive…

This early-phase trial tests an experimental drug called FXB0871 in about 138 adults with advanced solid tumors, including non-small cell lung cancer and liver cancer, that have stopped responding to standard treatments. The study has two parts: first, finding a safe dose, and se…

This study tests whether combining brain radiation with a targeted drug (dalpiciclib) and hormone therapy can help control breast cancer that has spread to the brain in people with HR-positive/HER2-negative disease. About 46 participants will receive the combination and be follow…

This study tests a new drug called AK138D1, given alone or with another drug (ivonescimab), in people with advanced breast cancer. The goal is to see if the treatment is safe and can shrink tumors. About 286 adults aged 18 to 75 will take part. This is an early-stage trial, so th…

This early-phase trial tests a new combination treatment for people with advanced breast cancer that has not responded to standard therapies. The treatment uses specially engineered immune cells (TRICK-NK) plus a targeted drug called T-Dxd. The study aims to find the safest dose …

This early-phase trial is testing an experimental therapy called WTX-212C, which uses specially engineered red blood cells to treat advanced solid tumors. The study will enroll 24 adults whose cancer has not responded to standard treatments. The main goal is to check safety and f…

This study tests whether a pharmacist-led program — including medication review, counseling, and follow-up — can help adult cancer outpatients take their medications correctly and avoid errors. One hundred participants will be split into two groups: one receives standard care plu…

This study tests whether adding a new drug called BEBT-209 to standard chemotherapy can shrink tumors and help people with advanced triple-negative breast cancer live longer. About 446 women aged 18 to 75 will be randomly assigned to receive either BEBT-209 plus two chemo drugs o…

This study looks at how well a drug called inavolisib works in real-world settings for people with a certain type of advanced breast cancer (HR-positive, HER2-negative, with a PIK3CA mutation). About 100 participants will take inavolisib along with hormone therapy, sometimes with…

This early-stage trial tests a new drug called CT-202 in people with advanced triple-negative breast cancer, colorectal cancer, or bladder cancer that has come back or spread. The drug is a bispecific antibody designed to help the immune system attack cancer cells that have a pro…

This early-phase study tests a new drug called KIVU-305 in people with advanced solid tumors that have stopped responding to standard treatments. The drug is designed to target and attack cancer cells while sparing healthy ones. The main goal is to find a safe dose and see if the…

This phase 2 study tests whether a new drug called JSKN003 works better than the current standard therapy for people with HER2-positive breast cancer that has returned or spread. About 60 adults who have not had prior treatment for advanced disease will receive either JSKN003 or …

This study tests a new combination of drugs (zanidatamab, tucatinib, and chemotherapy) in people with advanced HER2-positive breast cancer that cannot be removed by surgery or has spread. The goal is to find the safest dose and see if the treatment shrinks tumors. About 24 adults…

This study tests a new type of breast-conserving surgery that uses a small camera inserted through a hidden armpit incision to remove tumors, compared to the standard open approach. About 1,366 women with early-stage breast cancer will be randomly assigned to one of the two surge…

This phase 2 trial tests whether adding a targeted drug (axatilimab) and radiation to the immunotherapy pembrolizumab can help shrink tumors in people with metastatic triple-negative breast cancer who have already tried immunotherapy. About 34 participants will receive all three …

This study tests whether a special PET scan (HER2-PET) can help doctors personalize treatment for early-stage HER2-positive breast cancer. After two cycles of standard therapy, the scan results will determine if patients need stronger or milder treatment. The goal is to improve t…

This study tests a personalized approach for people with HER2-positive breast cancer. After two cycles of standard therapy, those whose tumors shrink less than 40% will switch to a new drug combination (SHR-A1811 plus pertuzumab) for four more cycles before surgery. The goal is t…

This study tests whether an artificial intelligence (AI) model can choose the best combination of targeted drugs for women with HER2-positive breast cancer before surgery. About 280 women with early or locally advanced breast cancer will be randomly assigned to either AI-guided t…

This early-stage trial tests crotoxin, a protein from rattlesnake venom, given intravenously to 24 adults with advanced solid tumors that have not responded to standard therapy. The main goal is to see if a slow dose increase can make the drug safer and better tolerated. Research…

This study tests whether a drug called edaravone dexborneol can help people who have a stroke while also having active cancer. The drug is given by IV twice a day for 10-14 days. Researchers will check if it improves recovery and is safe. About 144 adults aged 18-80 will take par…

This study compares two chemotherapy drugs—gemcitabine and paclitaxel—in Black Caribbean women with metastatic triple-negative breast cancer. The goal is to see if gemcitabine, usually used later, works better as a first treatment. 750 women from Jamaica, Trinidad, and Barbados w…

This study tests a new drug called ALK-N001 in 190 adults with advanced solid tumors that have not responded to standard treatments. The drug is given by IV every 2 or 3 weeks. Researchers will check if it shrinks tumors, how safe it is, and how the body processes it. The goal is…

This early-phase study tests an experimental drug called ZE94-0605 in about 60 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to find a safe dose and check for any signs of tumor shrinkage. The study is not yet recruiting.

This study is for people with advanced triple negative breast cancer, a type that is harder to treat. It tests a new oral liquid drug called BLEX 404 given with the chemotherapy drug Docetaxel. The goal is to find a safe dose and see if the combination helps shrink tumors. About …

This study looks at whether extra education and counseling helps women with HR+/HER2- early breast cancer take their prescribed medication, abemaciclib, more consistently. About 257 women will either receive standard care or additional coaching. The main goal is to see if coachin…

This early-phase trial tests a drug called CAN1012 in 24 people with pre-cancerous breast conditions (DCIS or LCIS). The drug is injected directly into the lesion to activate the immune system. The main goal is to check safety and ensure the treatment doesn't delay necessary surg…

This study tests a new drug called KHN922 in people with advanced solid tumors that have not responded to standard treatments. KHN922 is an antibody-drug conjugate designed to target HER3 proteins on cancer cells and deliver two anti-cancer drugs directly to them. The trial will …

This trial is for people with ER-positive, HER2-negative advanced breast cancer whose disease has started to grow in a few spots while on hormone therapy and a CDK4/6 inhibitor. It tests whether adding targeted radiation (SABR) to those spots allows patients to stay on their curr…

This study tests a new drug, QLC5513, alone or with another drug (QL1706) in 60 women with advanced triple-negative breast cancer that has worsened after at least one prior treatment. The goal is to see if these drugs can shrink tumors or slow the cancer's growth. Participants wi…

This phase 3 trial compares an injectable form of letrozole (given every 3 months) to the standard daily oral pill, both combined with ribociclib, in 300 postmenopausal women with advanced HR-positive, HER2-negative breast cancer. The goal is to see if the injection works as well…

This early-phase trial is testing a new chemotherapy drug called RP-001 in 66 adults with advanced solid tumors, including colorectal and pancreatic cancers. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. It is an open-label study, …

This study tests an experimental drug called LRK-4189, given alone or with standard chemotherapy, for adults with advanced solid tumors that have not responded to prior treatment. The main goal is to check the drug's safety and find the best dose. About 120 participants will take…

This study tests a new drug, JCXH-211, injected directly into tumors along with an anti-PD-1 antibody given through an IV. It is for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if the combination is safe and tolerable …

This study looks at whether a genetic test (Prosigna®) can help decide if younger women with early, hormone-sensitive breast cancer need chemotherapy. About 3380 premenopausal women will either get standard treatment (chemo plus hormone therapy) or a treatment plan based on the t…

This study tests whether adding the immunotherapy drug camrelizumab to chemotherapy and radiation before surgery can eliminate all signs of early-stage triple-negative breast cancer. About 43 women with newly diagnosed, untreated disease will receive the combination for 12 weeks,…

This pilot study tests a device that uses short, high-frequency electrical pulses to shrink or destroy soft tissue tumors in people with metastatic breast cancer. The trial will enroll 20 adults with tumors near the skin that are at least 1 cm but no larger than 5 cm. The main go…

This Phase 2 trial tests a new drug called HLX43, which is designed to seek out and destroy cancer cells in people with advanced triple-negative breast cancer (TNBC). The study will test HLX43 alone or combined with other immune-boosting drugs. About 180 adults with TNBC that has…

This study tests whether adding ivermectin, a drug used for parasitic infections, can improve the immune response in people with solid tumors who are already receiving immunotherapy. About 80 adults will take either a moderate or high dose of ivermectin for four weeks alongside t…

This early-stage trial tests a new cell therapy called GK01 in 15 people with advanced solid tumors that have not responded to standard treatments. GK01 uses a patient's own immune cells, trained to attack their cancer. The main goal is to find a safe dose and check for side effe…

This study will follow 500 people with HER2-positive advanced breast cancer who are starting treatment with pyrotinib, a daily oral targeted therapy. Researchers want to see how well the drug controls the cancer and what side effects occur in everyday medical practice, not just i…

This early-stage trial tests a new biologic drug, SIG001, in 66 people with advanced solid tumors. The main goals are to check safety, find the right dose, and see how the drug behaves in the body. Participants receive SIG001 intravenously every two weeks and are monitored for si…

This study tests whether adding the immunotherapy drug pembrolizumab to usual post-surgery treatment can help prevent breast cancer from returning in people with early-stage triple-negative breast cancer who still had cancer after initial chemo and pembrolizumab. About 1,000 adul…

This early-stage trial tests a new oral drug called HLX97 in 138 people with advanced solid tumors (breast, prostate, or lung cancer) that have stopped responding to standard treatments. The main goals are to check safety, find the right dose, and see if the drug can slow tumor g…

This study tests whether taking vitamin C and coenzyme Q10 can prevent kidney damage in cancer patients receiving cisplatin chemotherapy. About 75 adults with various cancers who have not had chemo before will take these supplements alongside their treatment. The goal is to see i…

This early-phase study tests a new drug called JSKN016HC in about 42 adults with advanced solid tumors that have not responded to other treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. Participants must be in fairly …

This phase 2 trial will test a combination of two drugs—serplulimab (an immunotherapy) and SHR-A1811 (a targeted chemotherapy)—given before surgery to women with early-stage triple-negative breast cancer. The main goal is to see how many patients have no cancer left at the time o…

This study tests an experimental oral drug, BPI-572270, in 120 adults with advanced solid tumors (lung, colorectal, or pancreatic cancer) that have specific RAS gene mutations. The trial has two phases: first to find a safe dose and check for side effects, then to see if the drug…

This phase II trial tests whether combining multi-mode thermal therapy (heat treatment) with immunotherapy drugs can help people with HER2-negative breast cancer that has spread to the liver. The study will enroll 30 participants who have already tried at least one prior treatmen…

This study looks at whether adding pyrotinib to two standard drugs (trastuzumab and pertuzumab) can help control HER2-positive advanced breast cancer longer. About 42 adults with advanced disease will receive this combination as maintenance therapy after initial treatment. The ma…

This study tests a drug called sacituzumab tirumotecan in 20 people with triple-negative breast cancer that has spread to the brain. The drug is given through a vein twice a month. The main goal is to see if it can shrink brain tumors. This is an early-phase trial, so it focuses …

This study tests a new drug called LCB02A for people with advanced solid tumors that have a specific marker (CLDN18.2) and haven't responded to standard treatments. The drug is designed to deliver a toxin directly to cancer cells. The trial has two phases: first, finding the safe…

This phase 2 trial tests a new drug called HLX43 in 60 people with a common type of advanced breast cancer (HR+ HER2-) that has worsened despite standard hormone therapy. The drug is an antibody-drug conjugate that targets PD-L1 to deliver chemotherapy directly to cancer cells. T…

This phase II trial is testing whether giving the hormone therapy drug goserelin (Zoladex) as a shot in the upper buttock works as well as the standard belly injection for suppressing ovarian function in premenopausal women with hormone-positive breast cancer. About 98 patients w…

This early-phase study tests a new drug called QLS5308 in about 192 adults with advanced solid tumors that have spread and cannot be removed by surgery or radiation. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants m…

This phase 2 trial tests whether injecting the anesthetic levobupivacaine around the tumor and nearby nerves during breast cancer surgery can reduce the risk of the cancer returning. The study will include 760 women with triple-negative breast cancer who have had chemotherapy and…

This early-phase trial tests a new radioactive drug, 177Lu-INN805, in 10 people with advanced solid tumors (like head & neck, lung, breast, or sarcoma) that haven't responded to standard treatments. The main goals are to find a safe dose and check for side effects. Researchers wi…

This study tests an experimental drug called QLS5132, given with other cancer treatments, for people with advanced solid tumors like stomach, lung, endometrial, and ovarian cancers. The goal is to find safe doses and see if the combination shrinks tumors. About 626 participants w…

This study tests a new approach for women with a common type of early breast cancer (HR+/HER2-). Instead of standard chemotherapy before surgery, some participants will receive a combination of hormone therapy and a targeted drug (abemaciclib) based on their tumor's gene test res…

This early-phase trial tests a new type of cell therapy for people with metastatic HER2-positive breast cancer that has worsened after standard treatment. Researchers take a patient's own immune cells (T cells), add new genes to help them recognize and attack cancer cells, and re…

This early-phase trial tests whether combining the targeted drug trastuzumab deruxtecan (T-DXd) with precise radiation (SRS) is safe for people with HER2-positive breast cancer that has spread to the brain. Up to 20 participants will receive the drug by IV every three weeks along…

This early-phase trial will test the safety and tolerability of combining a CDK4/6 inhibitor (abemaciclib) with radiation therapy after surgery in 30 women with HR+/HER2- high-risk breast cancer. The study aims to find the highest safe dose of the drug when used alongside radiati…

This phase 2 trial tests a combination of two drugs—entinostat and oral paclitaxel—in 50 people with HR-positive, HER2-negative advanced breast cancer who have already tried 2 to 4 prior treatments. The goal is to see if the combo can delay cancer growth. Participants take both d…

This study tests a combination of two drugs, inavolisib and eribulin, in people with advanced triple-negative breast cancer that has a PIK3CA mutation and has not responded to at least one prior treatment. The goal is to see if the combination shrinks tumors and is safe. About 26…

This early-stage study tests a new drug called T320 in 150 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants receive T320 every two wee…

This early-stage study tests a new treatment for people with advanced ovarian cancer or other solid tumors that have come back or not responded to standard therapy. The treatment uses a patient's own immune cells that are genetically modified to better recognize and attack cancer…

This early-phase trial tests an experimental drug called ITC-6146RO in about 102 adults with advanced or metastatic cancers (like prostate, lung, or breast cancer) that have not improved with standard treatments. The study has two parts: first, finding a safe dose, then checking …

This study looks at whether a combination of ribociclib (a targeted drug) and hormone therapy can be as effective as chemotherapy followed by the same combo for people with a common type of early breast cancer (HR+/HER2-). Only patients whose blood tests show no signs of cancer D…

This study tests whether taking letrozole, a hormone therapy pill, for one year before surgery can shrink tumors and clear cancer from lymph nodes in postmenopausal women with early-stage, hormone-sensitive breast cancer. All 126 participants will take letrozole daily and then ha…

This phase 2 trial tests whether a new drug, trastuzumab-rezetecan, works as well as the established drug T-DXd in shrinking HER2-positive breast tumors before surgery. About 68 women with early or locally advanced breast cancer will receive one of the two drugs for 8 cycles, the…

This study tests whether a three-drug combination can help people with triple-negative breast cancer whose tumors stopped responding to immunotherapy. About 46 women will receive cromolyn, TQB2102, and panpulimab to see if tumors shrink or stop growing. The goal is to control the…

This Phase 2 trial tests whether adding the experimental drug QL1706 to standard platinum chemotherapy helps people with advanced triple negative breast cancer live longer without their disease getting worse. About 78 adults who have already had one or two prior treatments will b…

This study tests whether taking two drugs (imlunestrant and abemaciclib) before surgery can shrink tumors in people with a common type of breast cancer (ER+/HER2-). About 189 women aged 18-75 with early-stage breast cancer will join. The treatment is guided by a marker called Ki6…

This study compares a new drug, SHR-A1811, with a standard combination therapy (pyrotinib plus capecitabine) in 100 adults with advanced HER2-positive breast cancer that did not respond to the first-line treatment trastuzumab. The goal is to see which approach better delays cance…

This early-phase trial tests a new type of cell therapy called CAR-Macrophages in 20 adults with advanced solid tumors. The immune cells are modified to target specific markers on cancer cells (HER2, PSMA, FAP) and are given by IV. The main goals are to check safety, find the bes…

This study tests whether taking the oral drug everolimus after standard chemotherapy can help prevent breast cancer from coming back in people with a specific subtype of triple-negative breast cancer called LAR. The trial will enroll 904 women who have had surgery for early-stage…

This study is for people with HER2-negative breast cancer whose tumors did not shrink after initial chemotherapy. Researchers are testing whether adding an immunotherapy drug (toripalimab) and targeted radiation before and after surgery can improve outcomes. About 110 participant…

This study tests whether a new quarterly injection of letrozole delivers the same amount of medicine into the body as the standard daily pill. It involves 120 postmenopausal women who have already completed at least 4-5 years of hormone therapy for early breast cancer. The goal i…

This early study tests a new treatment called CAT-101, which uses a patient's own immune cells (dendritic cells) loaded with a cancer protein (mKRAS) to help the body fight tumors. It is for people with advanced pancreatic cancer or other solid tumors that have a specific KRAS mu…

This Phase 3 trial tests whether adding the experimental drug NTQ1062 to standard hormone therapy (fulvestrant) can slow or stop the growth of advanced HR+/HER2- breast cancer in people whose cancer has returned or worsened after hormone therapy. The study includes 210 adults wit…

This early-phase study tests a new drug called JSKN027 in 250 adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. The study focuses on colorectal, lun…

This study tests whether adding famitinib to SHR-A1811 works better than SHR-A1811 alone for people with a certain type of advanced breast cancer (HR+/HER2-) that no longer responds to CDK4/6 inhibitors. About 248 women aged 18-70 will take part. The goal is to see if the combina…

This Phase 2 trial tests a new antibody drug (QL1706) combined with chemotherapy in 40 people with early triple-negative breast cancer. The treatment is tailored based on how the tumor responds after initial cycles, with the goal of avoiding certain heart-damaging drugs if possib…

This study looks at two powerful drugs, sacituzumab govitecan (SG) and trastuzumab deruxtecan (T-DXd), for people with a certain type of advanced breast cancer (HER2-low/TROP2-high). The goal is to find out which drug works best when given first and how to switch if the first sto…

This phase 2 trial tests a personalized approach for early-stage, hormone receptor-positive breast cancer. Participants receive a combination of CDK4/6 inhibitors and endocrine therapy before surgery. A blood test (ctDNA) is used to monitor tumor DNA and may help decide if chemot…

This study tests whether a drug called RC48, combined with chemotherapy, works better than standard treatments for women with advanced HER2-positive breast cancer whose disease has progressed after prior therapy. About 268 participants will be randomly assigned to receive either …

This early-phase trial tests a new drug called TPD3310 in 112 people with advanced solid tumors that have not responded to standard treatments. The study aims to find a safe dose and check for early signs of tumor shrinkage. Participants receive weekly injections over 28-day cycl…

This early-phase study tests a new drug called QLS5316 in about 300 adults with advanced solid tumors (such as colorectal, stomach, head and neck, or lung cancer) that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, a…

This early-phase study tests whether a new cell therapy called B7-H3 CAR T cells is safe and can help children and young adults whose solid tumors have returned or stopped responding to standard treatments. About 40 participants will receive their own immune cells that have been …

This early-stage trial tests a procedure called microtransplantation (MST) combined with chemotherapy in 10 adults with advanced or relapsed solid tumors. The goal is to see if MST can help control the disease and improve recovery of blood cells after chemo. The study focuses on …

This study tests whether a remote temperature monitor can help detect fever early in children undergoing chemotherapy who are at risk of a serious infection called febrile neutropenia. About 30 children from families with social or emotional challenges will either use a wearable …

This early-stage trial tests a personalized cell therapy for adults with advanced solid tumors that have not responded to standard treatments. Doctors take immune cells from a patient's own tumor, grow more of them in the lab, and then infuse them back after a short course of che…

This early-phase trial tests a new therapy called TCR-T cells, which are immune cells engineered to recognize and attack cancer cells with specific KRAS mutations (G12V or G12D). The study will enroll 25 adults with advanced solid tumors (like colorectal or lung cancer) who have …

This study tests whether adjusting cancer drug doses for people with the Duffy null blood trait can reduce treatment delays and dangerous fevers. About 90 participants with multiple myeloma or triple-negative breast cancer will receive standard chemotherapy with modified dosing g…

This study tests an experimental pill called ZL-85FA in people with advanced solid tumors (breast, ovarian, fallopian tube, primary peritoneal, or prostate cancer) that have not responded to standard treatments. The trial has two phases: first, finding a safe dose, then checking …

This early-stage trial tests a new drug called FXS887 in 14 people with advanced solid tumors that have stopped responding to standard treatments. The drug works by blocking a protein (ATR) that cancer cells need to repair their DNA. The main goals are to check safety, find the r…

This phase 2 trial tests a combination of three drugs (neratinib, fulvestrant, and eribulin) in 35 women with a specific type of advanced breast cancer (HR+/HER2+) that has stopped responding to the drug trastuzumab deruxtecan. The goal is to see if this new combination can shrin…

This study tests a new drug, HX111, in about 70 people with advanced solid tumors or lymphoma that has not responded to other treatments. The goal is to find a safe dose and see if the drug can shrink tumors. It is an early-stage trial, so the main focus is on safety and side eff…

This study will develop and test an AI model that combines MRI, ultrasound, digital pathology, and patient data to predict how well breast cancer responds to neoadjuvant therapy. Researchers will analyze data from 1,800 participants across multiple centers. The goal is to help do…

This early-phase study tests a new imaging agent that targets a protein called TROP2, found on many cancer cells. About 40 adults with metastatic bladder, breast, or lung cancer will receive the agent to see where it goes in the body. The goal is to see if this tracer can help do…

This early-stage study will test a new radioactive tracer called [89Zr]DFO-YS5 in 40 people with nerve sheath tumors, bladder cancer, or other advanced solid tumors. The tracer is designed to bind to cancer cells and show up on PET scans, potentially making tumors easier to see. …

This study tests a new radioactive tracer called 68Ga-FAPI-PSMA for PET/CT scans to see if it can find and stage solid tumors (like prostate, liver, and ovarian cancers) better than current tracers. About 20 adults with suspected or confirmed tumors will receive the tracer and ha…

This study will test if artificial intelligence can create clear breast MRI images without using contrast dye. Researchers will use a special type of MRI scan (diffusion-weighted imaging) to generate synthetic images that might help diagnose breast cancer. If successful, this cou…

This study tests whether a special ultrasound technique (super-resolution imaging) can predict if breast cancer will completely respond to chemotherapy after just one cycle. Researchers will enroll 150 women with invasive breast cancer scheduled for chemotherapy. The goal is to s…

This study tests an artificial intelligence (AI) system that analyzes breast images (digital breast tomosynthesis) to help doctors diagnose breast cancer more accurately. Researchers will train the AI on thousands of images from 5000 women to detect tumors, tell benign from malig…

This study looks at whether adding an MRI to the yearly mammogram can help find breast cancer earlier in women with dense breasts. Participants will have a mammogram and a risk score calculated from it. Those with a high risk score will be offered an MRI. The goal is to see if th…

This study tests a new type of PET/CT scan that uses a special tracer to see if HER2-positive breast cancer has been completely eliminated after chemotherapy and targeted therapy. The goal is to see if the scan can accurately predict which patients have no cancer left, potentiall…

This study tests a new radioactive tracer called 68Ga-MY for PET scans. It targets a protein (5T4) found on many cancer cells but rarely on healthy cells. About 20 people with lung or breast cancer will get both a standard FDG scan and a 68Ga-MY scan. Researchers will compare the…

This study compares a new type of PET scan (FAPI) to the standard PET scan (FDG) in 15 people with metastatic invasive lobular breast cancer. The goal is to see if the new scan finds more cancer spots. Each participant will get both scans within a few weeks, and doctors will comp…

This study will compare two types of scans—PET/CT and CT—to see which is better at finding distant spread of breast cancer. About 97 patients with advanced breast cancer will receive both scans within a few weeks. The goal is to improve early staging and guide treatment to improv…

This study tests whether a new MRI contrast agent, gadopiclenol, can detect brain metastases earlier than standard methods in 180 patients with advanced lung, breast, or skin cancer. Participants will receive screening brain MRIs to compare diagnosis timing and accuracy. The goal…

This study will test if a new type of MRI scanner, called Field-Cycling Imaging (FCI), can accurately measure the size of breast tumors in people with ductal carcinoma in situ (DCIS). Twelve participants will receive both a standard MRI and an FCI scan before surgery. The results…

This study tests whether regular blood tests (ctDNA) can find triple-negative breast cancer recurrence earlier than standard follow-up. Thirty patients who had surgery for stage II or III TNBC will be randomly assigned to either standard care or standard care plus ctDNA testing e…

This study tests a new radioactive tracer called 68Ga-DOTA-BLP for PET scans to see PD-L1 levels in tumors. PD-L1 helps cancer hide from the immune system, and knowing its levels can guide immunotherapy. The study will include 50 adults with confirmed cancer and suspicious spots …

This study tests a new PET imaging agent, 68Ga-cPP-BCH, to detect PD-L1 protein levels in tumors of people with lung cancer, melanoma, or other solid tumors. The goal is to see if this scan can identify who might benefit from anti-PD-1/PD-L1 immunotherapy without needing a tissue…

This study tests a new radioactive imaging agent called 68Ga-SFB6-ZN01, which is designed to attach to a protein found on many cancer cells. 98 adults with confirmed or suspected cancer will receive a single injection of the agent and then have a PET/CT scan. The goal is to see i…

This early study tests a new radioactive antibody called NTH-2403 in 16 people with advanced colorectal, head and neck, lung, or triple-negative breast cancers. The antibody targets a protein found on cancer cells and their supporting cells, allowing doctors to see tumors on scan…

This study will test a new imaging agent called 68Ga-B6FA-01, which targets two different markers on cancer cells and their surroundings. The goal is to see if this probe can improve PET/CT scans for diagnosing and staging solid tumors. About 100 adults with newly diagnosed or re…

This study tests a new type of PET scan using a tracer called 68Ga-FAPI-46 to find cancer that has spread in patients with lobular breast cancer. Standard scans often miss these metastases. The trial will enroll 45 adults whose standard PET scan was negative or unclear, and see i…

This study tests a new device called VTM that uses infrared light to look for early signs of breast cancer, possibly before a lump appears. Researchers will compare VTM scans with standard mammograms in 120 women with breast cancer. The goal is to see if VTM can find tumors and b…

This study will test whether a 12-week program of supervised aerobic and strength exercises can prevent heart problems in 60 adults undergoing chemotherapy for cancer. Participants will be split into an exercise group and a usual-care group. Researchers will measure heart functio…

This study tests whether light therapy (photobiomodulation) can prevent mouth sores in children receiving chemotherapy. Fifty children aged 0-30 will receive daily light treatments during hospital stays and at home. Researchers will check if the therapy is easy to use and accepta…

This study tests whether electroacupuncture (acupuncture with mild electrical pulses) combined with tiny thumbtack needles can prevent peripheral neuropathy—numbness, tingling, or pain—caused by chemotherapy in people with advanced cancer. The trial enrolls adults with stage IV b…

This study will test different methods to prevent infections and other problems from central lines (tubes placed in large veins) in 2,500 patients. It compares special antimicrobial caps and a skin anchor device against standard care. The goal is to find the best ways to keep pat…

This study tests a personalized program supported by a mobile app to prevent heart damage caused by breast cancer treatments. Researchers will enroll 102 women recently diagnosed with early-stage breast cancer who are at risk for heart side effects. The program uses artificial in…

This study tests whether providing online webinars, digital tools, and a logbook can help adults at high risk for breast cancer become more physically active. Participants (200 women aged 30-69) will either receive the full motivation package or just standard activity recommendat…

This study tests whether low doses of two hormone-blocking drugs, exemestane and tamoxifen, can help prevent breast cancer in postmenopausal women at high risk. About 140 women will take one of the two drugs for a year, and researchers will measure side effects and quality of lif…

This study tests a surgical technique done at the same time as breast cancer lymph node removal to prevent arm lymphedema (chronic swelling). The procedure uses a small flap of tissue from the side of the chest to rebuild the armpit area and support fluid drainage. One hundred hi…

This study will test whether a mobile app called RestoreMe can help cancer patients get personalized nutrition and activity advice. Researchers plan to enroll 150 adults who are about to start, are currently receiving, or have completed cancer treatment. Participants will use the…

This pilot study tests whether adding a specialized radiation technique called Lattice Radiation Therapy (LRT) to standard palliative radiation can safely shrink large tumors (at least 4.5 cm) in adults. The study will enroll 25 people with various cancers who are already schedul…

This study tests if eating only within an 8-hour window each day (time-restricted eating) can reduce treatment side effects and improve quality of life for people with solid tumors starting adjuvant therapy after surgery. Fifty adults will be randomly assigned to follow this eati…

This study will test a comfort menu and cart for older adults (60+) receiving cancer treatment at a hospital in Brazil. The cart offers items like blankets, pillows, and hygiene kits to improve comfort. Researchers will compare patient and staff experiences before and after the c…

This study tests whether a dietary supplement called Redsenol-1 Plus can safely reduce fatigue in adults who have had cancer treatment. 72 participants will take either the supplement or a placebo for 12 weeks. The main goal is to see if fatigue levels improve, as measured by a s…

This study compares three techniques—ultrasound, wire, and magnetic seed—to help surgeons remove non-palpable breast tumors more accurately during breast-conserving surgery. About 1,300 adult women with early-stage breast cancer will be randomly assigned to one of the three metho…

This study tests a simple screening tool to identify cancer patients struggling with medical costs. Those who screen positive will be connected to financial counseling and resources at their hospital. The goal is to make it easier for patients to afford their care and reduce fina…

This study tests whether a tailored coaching program can help adolescents and young adults (ages 15-24) with cancer take their oral medications as prescribed. Participants will work with a coach over four sessions to identify and overcome barriers to adherence, using an electroni…

This study tests whether keeping older patients (65+) at a slightly higher body temperature (36.8°C) during major cancer surgery can reduce the risk of delayed neurocognitive recovery—a kind of short-term confusion or memory decline that can happen after surgery. About 1,500 part…

This phase II trial tests whether low-dose psilocybin, a compound from magic mushrooms, combined with psychotherapy is safe and effective for easing chronic pain in cancer patients who already take opioids. Twenty adults with active cancer and moderate to severe pain will receive…

This study tests whether a cannabis gummy can improve sleep and quality of life in 50 cancer patients who have trouble sleeping. Participants will either take the gummy or receive usual care for 5 weeks. The goal is to see if the gummy is safe and helps with sleep, while also che…

This study tests whether a non-invasive technique called transcutaneous electrical acupoint stimulation (TEAS) can prevent or treat sleep problems after cancer surgery. TEAS uses mild electrical pulses on specific points on the skin, based on acupuncture, without needles. The tri…

This study looks at whether adding the drug bupropion (Wellbutrin) to standard hormone therapy can help women with early-stage breast cancer who have lost interest in sex. About 100 women will be randomly assigned to receive either their usual hormone therapy alone or with buprop…

This study compares two types of nerve blocks given before breast cancer surgery (modified radical mastectomy) to see which one helps patients recover better. Sixty women will receive either a newer block called subtransverse interligamentary plane block or the standard thoracic …

This study will test a structured early rehabilitation program for women who have had breast cancer surgery. The program includes education, gentle exercises starting the day after surgery, and home-based workouts with monitoring. Researchers want to see if it is safe and helps w…

This study tests whether sophrology, a relaxation technique using gentle movements, breathing, and positive visualization, can reduce anxiety in cancer patients undergoing radiation therapy. Fifty-four adults with various cancers will be offered sophrology sessions during their t…

This study tests whether sucking on ice chips during chemotherapy can prevent or reduce the severity of painful mouth sores (oral mucositis) in cancer patients. 102 adults receiving 5-fluorouracil or methotrexate will be randomly assigned to either get ice chips during infusion p…

This study tests a group therapy program called LiveWell mBC for women with metastatic breast cancer who are feeling distressed. The program uses adapted Dialectical Behavioral Therapy (DBT) skills to help manage emotions and uncertainty. 48 women will be randomly assigned to eit…

This study tests whether a supervised strength training program can improve quality of life, physical function, and mental health in children with cancer. Twenty participants under 18 who are currently on treatment or dealing with after-effects will do two 50-minute sessions per …

This study tests whether learning progressive muscle relaxation and deep breathing exercises can improve sleep for cancer patients receiving chemotherapy. About 40 adults aged 40-60 with poor sleep will be split into two groups: one gets relaxation training plus usual care, the o…

This study tests whether a 6-week dance-based exercise program can reduce nerve pain and improve quality of life in cancer patients who have nerve damage from chemotherapy. About 76 adults with solid tumors will either join the dance program or receive usual care. The goal is to …

This study tests a new smart home system that uses artificial intelligence to deliver cognitive behavioral therapy for insomnia to young adult cancer survivors. The system includes a smart speaker, smart lighting, and a special Wi-Fi router. Researchers will compare it to standar…

This observational study will follow 50 people receiving chemotherapy that often causes nausea and vomiting. Researchers want to see if those who use medical cannabis on their own have less nausea, better appetite, and fewer other side effects compared to those who don't use it. …

This study tests a spiritual health program called PATH for cancer patients struggling with feelings of disconnection, loss of meaning, or existential distress. Twenty adults with any stage of cancer will attend six workshops combining role-playing, psychology, and dignity therap…

This study tests whether a 14-week personalized exercise program can improve mobility, strength, and quality of life in frail adults aged 65 and older with cancer who have recently been hospitalized. One hundred participants will either follow the adapted physical activity progra…

This study tests whether live, online group strength training can help older cancer survivors (age 65+) who have trouble with daily activities. 150 participants will be split into three groups: immediate strength training, delayed strength training, or stretching. The goal is to …

This study looks at whether inhaling isopropyl alcohol (rubbing alcohol) can help reduce nausea in cancer patients. About 112 adults with cancer who rate their nausea as at least 4 out of 10 will be asked to inhale the alcohol and report any changes. The goal is to find a quick, …

This study tests whether walking with a robot dog can improve sleep, reduce fatigue, and enhance quality of life in children aged 2-7 who are undergoing cancer treatment. Forty children will be randomly assigned to either robot-dog-assisted walks or usual care. The goal is to see…

This pilot study will give 20 early-stage cancer patients a preloaded cash card with $1,000 each month. The goal is to see if this simple cash support can prevent financial hardship, like debt or missed rent, and improve treatment outcomes. Researchers will measure how many peopl…

This study tests whether a gentle electrical stimulation on the ear (called taVNS) can reduce joint and muscle pain caused by aromatase inhibitors, a common breast cancer treatment. 216 women with hormone-positive breast cancer will receive either real or sham stimulation daily f…

This study tests a new drug called INB301 in people with cancer who are losing weight and muscle (cancer cachexia). The goal is to see if it is safe and can help patients gain or maintain weight. About 146 adults with solid tumors like lung, pancreatic, or colorectal cancer will …

This study tests whether a specially designed AI chatbot can lower anxiety and trauma-related distress in adults recently diagnosed with cancer. Participants will use the chatbot for 12 weeks and complete surveys about their feelings and needs. The goal is to see if this digital …

This Phase 3 trial tests whether electroacupuncture—thin needles with mild electric pulses—can ease cognitive problems like memory loss and trouble focusing in cancer survivors. 168 participants will be assigned to real electroacupuncture, sham (fake) acupuncture, or a waitlist. …

This study tests whether a daily 50mg dose of sildenafil (Viagra) can prevent or reduce the fatigue and cognitive problems (brain fog) that often come with cancer treatment. The trial will enroll 30 women with ER+/HER2- breast cancer, aged 30-50, and track their symptoms using qu…

This study tests whether training doctors in shared decision-making and giving patients educational materials improves treatment conversations for HER2-negative metastatic breast cancer. 120 patients starting first-line therapy will be randomly assigned to receive the program or …

This study tests whether a 15-minute hand and foot exercise routine can reduce nerve pain caused by Taxane chemotherapy in cancer patients. Fifty-eight adults with mild nerve symptoms will either do the exercises plus standard care or receive standard care alone. Researchers will…

This study tests whether THC (with or without CBD) can improve sleep in people with solid organ cancer who have insomnia. About 69 participants will receive either THC, a THC/CBD mix, or a placebo as a liquid under the tongue. The goal is to see if these cannabis-based compounds …

This study tests whether a 6-week gardening and nutrition program can improve quality of life for cancer survivors. Fifteen participants will attend weekly group sessions with gardening, cooking demos, and mindfulness. The main goal is to see if the program is practical and liked…

This pilot study tests whether freeze-dried miracle fruit (MiraBurst) can improve taste changes in people with solid tumors undergoing cancer treatment. About 45 adults will take one mini-square before each meal for 90 days. The goal is to see if this simple supplement can ease a…

This study tests a group-based program for people with cancer that focuses on managing energy, doing meaningful activities, and improving quality of life. About 30 adults with cancer will take part in workshops and hands-on sessions in a community setting. The goal is to see if t…

This study tests whether a personalized cognitive training program can reduce 'chemobrain' in breast cancer patients receiving chemotherapy. 75 women will be split into two groups: one gets the training plus a healthy lifestyle leaflet, the other gets only the leaflet. Researcher…

This study tests whether silkworm pupa tablets can improve nutrition and reduce muscle loss (sarcopenia) in people who have completed cancer treatment. 480 participants will receive either the tablets or a placebo for 3 months. The main goal is to see if muscle strength and mass …

This study tests whether a low-level laser applied to specific points on the ear can improve sleep in women with breast cancer who have insomnia. Seventy participants will receive either real or sham laser acupuncture twice a week for five weeks. Sleep quality, fatigue, and mood …

This study tests whether a smartphone app called the Cancer Exercise app (CEA) can help cancer survivors become more physically active. About 750 adults who have finished cancer treatment will either use the app for 12 weeks or receive usual care. The goal is to see if the app bo…

This study tests whether a single early meeting with a psycho-oncology counselor can reduce anxiety and depression and improve quality of life in people recently diagnosed with cancer. About 148 patients will be randomly assigned to either receive this counseling plus standard ca…

This study tests a new surgical approach for women with early breast cancer who need a nipple-sparing mastectomy. If cancer is found in the nipple during surgery, doctors will remove the nipple but try to save the pigmented skin around it (the areola) and rebuild a new nipple rig…

This study tests whether megestrol acetate, a drug often used for appetite loss, can prevent or reduce severe tiredness in 132 women with advanced breast cancer who are starting a treatment called trastuzumab deruxtecan (T-DXd). Participants will receive either megestrol acetate …

This study tests a new drug called PDC-1421 to see if it is safe and helps with depression in people who have cancer. About 12 adults with mild to severe depression and stage I-III cancer will take the drug for up to 5 weeks. Doctors will check mood changes using a standard depre…

This study looks at whether adding psychosocial support to standard chemotherapy helps breast cancer patients feel better and respond better to treatment. About 160 Palestinian women with early-stage breast cancer will take part. Half will get usual care, and half will also recei…

This phase 2 trial tests JAK inhibitors (upadacitinib or tofacitinib) in 35 adults with solid tumors who have severe skin rashes from immunotherapy that didn't improve with steroids. The goal is to see if these pills can quickly relieve the rash and itching while allowing patient…

This trial tests an educational program called A-PACT for people with solid tumors who are at high risk of decline. Trained lay health workers coach patients on how to discuss their care goals and end-of-life wishes with their medical team. The study will see if this reduces unpl…

This study tests a special scanner that lets surgeons check, in real time during breast cancer surgery, whether all cancer has been removed. The goal is to reduce the need for a second operation. About 228 women with certain high-risk breast cancer types will take part. The scann…

This study compares two ways of giving a large-volume subcutaneous injection of targeted therapy (pertuzumab and trastuzumab) to 40 women with HER2-positive breast cancer. Each patient will receive one injection by a nurse using a stopwatch to mimic a steady speed, and another in…

This study explores whether equicoaching—a type of coaching with horses—can help young adults (ages 15-25) who finished cancer treatment feel more confident and reconnect with others. Ten participants will take part in the program and share their experiences through interviews an…

This study tests whether a supervised exercise program combining resistance training and walking can improve physical function, fitness, and quality of life in women with stage IV breast cancer. 78 women currently on medical treatment will be randomly assigned to either the exerc…

This study tests whether a whole food, plant-based diet combined with behavioral education can improve quality of life and diet adherence in 60 women with metastatic breast or endometrial cancer. Participants are randomly assigned to either the plant-based diet with support or a …

This study tests whether a digital platform called Beacon can help doctors better manage symptoms in people with advanced cancer. About 40 patients will wear smartwatches and answer questions about how they feel. The platform combines this data to give doctors a clearer picture o…

This study tests an educational program called SHARE-MC designed to help women with metastatic breast cancer address sexual health issues. About 96 women will take part in group video sessions or receive an informational booklet. The goal is to see if the program improves sexual …

This study tests whether personalized cooking and food guidance can help slow muscle loss in people with advanced cancer who are on chemotherapy. About 200 adults will be split into two groups: one gets standard nutrition care plus exercise advice, and the other gets the same plu…

This study aims to create and test a virtual group program for young adults (ages 18-39) who have had cancer and are experiencing post-traumatic stress symptoms. The program will be developed with expert feedback and then tested with 80 survivors to see if it is feasible and help…

This study tests whether virtual reality (VR) guided imagery can reduce pain in people with stage III or IV breast cancer. Ninety participants will be split into three groups: one using immersive VR (headset), one using non-immersive VR (computer screen), and a control group rece…

This study tests whether adding electroacupuncture and ear acupoint pressing beans to a standard opioid painkiller can better relieve severe cancer pain that doesn't respond to usual treatments. About 30 adults with refractory cancer pain will receive the combination for two week…

This study tests a digital exercise program called EMPOWER for children aged 3 to 6 who are undergoing cancer treatment. The goal is to see if the program can help them stay physically active, improve their motor skills, and boost their quality of life. Parents and nurses will al…

This study is testing a smartphone app called I-STAMP that helps people with advanced cancer keep track of their pain and medications. About 73 participants will use the app and rate how easy it is to use and how helpful it is. The goal is to see if the app can make managing canc…

This study tests whether acupuncture can safely reduce hot flashes in women with hormone receptor-positive breast cancer who are on hormone therapy. Sixty patients will receive either real or sham acupuncture three times a week for eight weeks, then be followed for 16 more weeks.…

This study tests whether a cannabis extract oil containing THC and CBD can reduce the overall symptom burden in people with advanced solid tumors who are already taking strong painkillers. About 156 participants will receive either the cannabis oil or a placebo for 8 weeks. The m…

This study tests a nurse-delivered patient navigation program for women with HER2+ metastatic breast cancer who are taking a specific combination of drugs. The program provides education, symptom management tips, and coping strategies over about 12 weeks. Researchers want to see …

This study tests whether a 6-month supervised home exercise program is feasible and safe for adult cancer patients. Participants will cycle and do resistance training three times a week at home, with regular supervision from a physiotherapist. The goal is to see if patients can s…

This study tests whether an online sexual health video series can help women newly diagnosed with breast cancer feel more confident talking to their doctors about sexual health. About 200 women will be randomly assigned to watch the videos or receive usual care. Researchers will …

This phase II trial tests whether giving preventive medications (loperamide for diarrhea and cetirizine for rash) can reduce common side effects of the cancer drug capivasertib when combined with fulvestrant. About 108 adults with HR+/HER2- metastatic breast cancer will participa…

This study tests whether a personalized exercise program, tracked by a smartwatch, can help reduce fatigue in people who have finished chemotherapy for certain cancers (breast, colorectal, ovarian, pancreatic, or gastric). About 98 participants will be randomly assigned to either…

This study tests whether a simple home exercise program done for at least three weeks before breast cancer surgery can help women recover better. 54 women with early-stage breast cancer will be randomly assigned to either the exercise program or usual care. Researchers will measu…

This study looks at whether a simple, non-needle ear acupressure technique can lower anxiety and pain in women having breast surgery after a first breast cancer diagnosis. About 66 women will either get standard care or standard care plus ear acupressure. The goal is to see if th…

This study tests whether adding telephone health coaching to a symptom management handbook helps reduce symptom burden and improve quality of life for people with metastatic breast, GI, or melanoma cancer and their caregivers. About 200 participants will be split into two groups:…

This study tests whether a personalized diet can improve quality of life in 100 women with advanced gynecologic or breast cancer who are receiving antibody-drug conjugate therapy. Participants will either follow a diet tailored to their needs or receive general Mediterranean diet…

This study tests whether a virtual exercise program with peer support helps older adults (60+) with cancer become more active and feel better. Participants are matched with a peer and receive guidance from exercise professionals or just peer support, compared to usual care. Over …

This study tests whether a handheld palm stimulator can reduce pain, fear, and anxiety when cancer patients get an IV for chemotherapy. About 90 adults will be randomly assigned to either squeeze the device during the procedure or receive standard care. The goal is to provide a l…

This study tests a flexible palliative care program for people with advanced heart failure or certain cancers. The program adds more team members—like a social worker or nurse—as symptoms get worse. The goal is to improve quality of life and match care to each person's changing n…

This study tests a 6-month online program for women with newly diagnosed breast cancer. The program includes daily exercise, mindfulness, and support via email and optional group sessions. Researchers want to see if it reduces psychological distress and improves well-being compar…

This study compares two ultrasound-guided nerve blocks—external oblique intercostal plane block and erector spinae block—for pain relief after liver surgery in cancer patients. Fifty-two adults will receive one of the two blocks, and researchers will measure pain scores and morph…

This study tests whether a traditional Chinese medicine hand-foot soak can reduce nerve pain and skin reactions caused by chemotherapy. About 300 adults with solid tumors who have these side effects will use the soak. The goal is to see if it improves symptoms and quality of life…

This study tests whether giving atropine before treatment can prevent diarrhea in people with advanced breast cancer receiving the drug sacituzumab govitecan. About 30 participants will receive atropine alongside their cancer therapy. The goal is to improve treatment tolerance an…

This study tests a 4-week art-based program that combines relaxation exercises with creative activities like emotion-color mapping and gratitude mandalas. The goal is to see if it reduces anxiety, improves emotion regulation, and lessens symptom burden in 60 adolescents aged 10-1…

This study tests a death education program for family caregivers of people with advanced cancer. The program includes four one-on-one sessions to help caregivers communicate about death, reduce anxiety and depression, and improve spiritual well-being. About 30 caregivers will tak…

This study tests a 5-week vision board program designed to increase hope and psychological strength in teenagers who have been undergoing cancer treatment for at least six months. Sixty adolescents aged 12 to 18 will be randomly assigned to either the vision board program or stan…

This study looks at two simple, drug-free ways to help reduce pain during bone marrow aspiration and biopsy, a common but painful procedure for diagnosing blood cancers. About 80 adult cancer patients will either fake cough, squeeze a stress ball, or receive standard care during …

This study looks at whether wellness coaching, delivered through a mobile app or in a group, can help women recently diagnosed with breast cancer adjust emotionally and feel better overall. About 124 women will take part, answering surveys before and after an 8-week program. The …

This pilot study tests an online program called Finding My Way-UK for people who finished curative cancer treatment in the past year. The program includes six self-guided modules on coping, emotions, and body image. Researchers will check if it's easy to use and if it helps with …

This study looks at whether melatonin or vitamin D can help prevent heart damage in breast cancer patients receiving the chemotherapy drug doxorubicin. About 90 women will be randomly assigned to take melatonin, vitamin D, or a placebo alongside their cancer treatment. The goal i…

This study looks at how the timing of a blood test that detects tumor DNA (ctDNA) affects understanding of prognosis and treatment choices in people with advanced HR+/HER2- breast cancer. Researchers will follow 400 participants to see how ctDNA levels and gene mutations relate t…

This study collects spinal fluid, blood, saliva, and tumor samples from 139 adults with HER2-positive or triple-negative breast cancer that has spread to other organs but not yet to the brain. Researchers will analyze these samples for tumor DNA that might predict when the cancer…

This study interviews bereaved parents and oncologists to understand how they discussed uncertainty during a child's cancer treatment. The goal is to find better ways for doctors and families to communicate about what the future may hold. Participants include parents whose child …

This study uses advanced 4D MRI scans to measure blood flow and heart function in adults with heart disease or cancer. Researchers aim to see if these detailed images can help predict how these diseases will progress. The study involves 1,000 participants who are already schedule…

This study looks at whether a person's body composition—like muscle mass and body fat—affects how accurately they are positioned during radiation therapy. Researchers will measure body composition in 120–150 cancer patients before and during treatment, and track daily positioning…

This study collects tumor tissue and blood samples from 120 cancer patients who are receiving or will receive immunotherapy. The samples will be stored in a biobank for future research to better understand how these treatments work. No direct treatment is given; the goal is to ga…

This study tests whether a routine digital screening followed by a supportive phone call can help cancer survivors get the emotional and social support they need after finishing primary treatment. Fifty adults who have completed cancer therapy will take part. The goal is to see i…

This study will survey 370 adult cancer patients about their knowledge, attitudes, and practices regarding physical exercise. The goal is to understand why many patients don't exercise enough and what barriers they face. Results will help create better exercise programs and possi…

This study looks at whether a blood test can predict how well the drug deruxtepruzumab works in people with advanced breast cancer that has low or ultra-low levels of a protein called HER2. Researchers will track cancer cells and HER2 levels in the blood of 100 patients during tr…

This study will observe 200 cancer patients who are already receiving immunotherapy (immune checkpoint inhibitors) along with radiotherapy. Researchers want to see how long the cancer stays under control and how patients fare overall, in everyday clinical practice rather than a s…

This study looks at whether tracking tumor DNA in the blood (ctDNA) can help doctors see how well breast cancer treatment is working before surgery. It will include 186 people with stage II-III HER2-positive or triple-negative breast cancer. Researchers will take blood samples at…

This study looks at how feeling overwhelmed by information and dealing with symptoms affects the sense of empowerment in 300 adult cancer patients getting outpatient chemotherapy. Researchers will use surveys to measure information overload, symptom severity, and empowerment leve…

This study will collect data from 500 cancer patients who are about to start immunotherapy. Researchers want to build a tool that can predict survival outcomes based on factors like combination treatments. The goal is to help doctors and patients make more informed decisions abou…

This study tests a digital tool called ReSPECT that helps teens and young adults with cancer talk to their doctors about sexual and reproductive health. The tool includes a pre-visit checklist and an informational website. Researchers want to see if it is practical and helpful fo…

This study will enroll 56 women with breast cancer to see if two different regional anesthesia techniques (paravertebral block vs. erector spinae plane block) cause different immune responses during surgery. Participants will receive one of the two blocks along with general anest…

This study tracks how the experimental drug AZD1390 moves through and leaves the body after a single dose. It involves about 8 adults with advanced solid tumors who are not currently on active cancer treatment. By using a tiny radioactive label, researchers can measure the drug i…

This study tests whether taking omega-3 supplements before surgery can change the types of fats found in breast tumors. About 35 adults with early-stage breast cancer will take the supplement for 4 to 28 weeks while also receiving standard cancer treatments. The goal is to see if…

This study will test whether whole-body MRI scans and blood tests for tumor DNA can better detect cancer progression in a type of breast cancer that is often missed by standard scans. Researchers will follow 43 people with metastatic invasive lobular carcinoma for up to 30 months…

This study will map the location of small blood vessels in the chest wall using bony and soft tissue landmarks. The goal is to help surgeons perform partial breast reconstruction more precisely after breast cancer surgery. The study will involve 20 women undergoing elective breas…

This study looks at the best ways to add supervised exercise programs into standard cancer care. Researchers will track how often doctors refer patients to exercise and how many patients take part. The goal is to see if this approach is practical and helps improve patients' physi…

This study tests a new chatbot designed to help cancer patients and their caregivers in rural areas find clear information about insurance, travel costs, and other financial aspects of cancer care. About 60 participants will be randomly assigned to use either a hybrid chatbot or …

This large observational study will follow 4,000 young cancer survivors (ages 15-39) across Europe to understand how different cancer treatments impact fertility, hormone function, and pregnancy outcomes. Researchers will also evaluate the safety and success of fertility preserva…

This study will collect data from up to 10,000 cancer patients across Europe to create better tools for predicting heart damage caused by certain cancer treatments. Researchers will use artificial intelligence alongside standard methods to develop risk scores that doctors can use…

This study will follow 3,000 young women (ages 15-39) with cancer to understand how treatments like chemotherapy and immunotherapy impact their fertility, pregnancy outcomes, and quality of life. Researchers will also look at the safety and success of fertility preservation metho…

This study looks at whether a special fasting schedule (eating only dinner) can make PI3K inhibitor drugs work better against metastatic breast cancer. Researchers will check if patients can stick with the fasting plan and study blood samples to see how fasting affects cancer cel…

This study tests whether a culturally tailored program can help Black women keep their mammogram appointments. About 176 women aged 40 and older who are scheduled for a screening mammogram will take part. The goal is to find better ways to reduce racial disparities in breast canc…

This study looks at how a special program, called the Geriatric Surgery Verification Program, works at the James Cancer Hospital. The program helps doctors and nurses better care for patients aged 65 and older who need cancer surgery. It includes checking for age-related issues l…

This study will test an artificial intelligence system designed to give early warning of cancer spreading to other parts of the body. Current imaging can only see larger tumors, but this AI analyzes routine scans and patient data to detect signs of microscopic spread. Researchers…

This study follows 1,000 young men (ages 15-39) diagnosed with cancer to understand how treatments affect their fertility and hormone levels over time. Researchers will collect medical history, semen samples, and blood tests before and after therapy to identify who is at risk for…

This phase 2 trial is testing whether blood tests and imaging scans can tell if chemotherapy is working in people with early-stage triple-negative breast cancer before they go to surgery. The study will enroll 200 participants who will receive a combination of chemotherapy drugs …

This study is testing a new tool to help older adults (65+) with metastatic breast cancer and their care partners make treatment decisions together. Researchers want to see if the tool is acceptable, appropriate, and practical for use. The study involves 150 participants and focu…

This study looks at tumor samples from 55 women with early-stage breast cancer to find early signs of whether chemo-immunotherapy is working. By analyzing individual cells before, during, and after treatment, researchers hope to identify markers that predict response or resistanc…

This study will survey about 950 men who stored sperm at a French fertility center before cancer treatment between 2010 and 2024. Researchers want to know how many later became fathers, whether naturally or with medical help, and if they used their frozen sperm. The goal is to be…

This study aims to understand why breast cancer in young women is often more aggressive. Researchers will look at how pregnancy and breastfeeding might influence the disease. They will collect information from 1,000 women aged 45 or younger (and a comparison group aged 55+) with …

This study will track muscle deterioration in about 40 hospitalized cancer patients using simple tests like grip strength, electrical muscle readings, and body composition scans. Researchers hope to find patterns that help identify muscle loss early, which could lead to better su…

This study will review medical records of about 240 adults in Kazakhstan with HER2-positive metastatic breast cancer to see how they were treated and how well they did. Researchers will look at treatments given in routine care (except one specific drug) and track outcomes like ho…

This pilot study tests whether a biology-guided therapy recommendations report can help doctors choose treatments for advanced hormone receptor-positive breast cancer that cannot be removed by surgery or has spread. Researchers will analyze tumor tissue from 20 patients to create…

This study will follow 2,200 young women (aged 40 or younger) who had breast cancer and carry a mutation in a breast cancer gene other than BRCA1/2. Researchers want to see if getting pregnant after diagnosis affects the cancer's return. The study does not test any drug or treatm…

This early-stage study looks at whether taking oral paclitaxel with encequidar on an empty stomach or after a meal changes how much drug gets into the body. About 46 adults with advanced solid tumors (like breast, lung, or stomach cancer) will take the drugs in different sequence…

This study tests whether a new collimator (a filter that directs gamma rays) on a special camera can produce clearer whole-body images for cancer patients. About 18 adults with multiple known cancer lesions will receive standard scans using technetium-99m, lutetium-177, or iodine…

This study looks at 200 women with early-stage triple-negative breast cancer to find immune markers in tumors and blood that predict whether immunochemotherapy will work well. Researchers will compare those who have a complete response to those who don't, aiming to guide more per…

This study looks at how gut bacteria affect diarrhea and other stomach issues in people with HR+/HER2- breast cancer taking the drug abemaciclib. In the first part, researchers will collect stool samples to track bacteria changes. In the second part, a small group will try eating…

This study aims to understand what might cause breast cancer in men by collecting genetic, environmental, and lifestyle information from 120 male volunteers who are relatives of male breast cancer patients. Participants will fill out a questionnaire and provide a blood sample for…

This study surveys 240 breast cancer patients to understand how they use herbs and supplements alongside standard treatments like chemo or hormone therapy. Researchers want to see if ethnicity influences which products people take. The goal is to gather information, not to test a…

This study looks at women with a very early form of breast cancer called DCIS. It uses a special test to find those at low risk of the cancer coming back. The goal is to see if these low-risk women can skip radiation therapy after their lump-removal surgery without a meaningful i…

This study looks at how diet and gut bacteria affect treatment outcomes in women with early-stage triple-negative breast cancer. Researchers will collect stool, blood, and tumor samples from 300 participants before, during, and after chemotherapy and immunotherapy. The goal is to…

This study is building an AI tool called ACTIVATE that scans electronic health records to find cancer patients who may be eligible for clinical trials. Researchers will test whether sending alerts to doctors increases the number of patients starting trials. The goal is to make it…

This study looks at how platinum-based chemotherapy can cause permanent hearing loss in cancer patients, and whether people from poorer backgrounds are more affected. Researchers will test hearing and thinking skills in 172 patients from North West England before and after treatm…

This study tests whether sending automated messages to cancer patients after they leave the hospital can help them use urgent oncology care instead of the emergency room. About 200 patients will receive reminders via MyChart and text in English or Spanish. Researchers will track …

This study looks at how adults getting chemotherapy use digital media and how well they understand online health information. Researchers will survey 80 patients about their digital habits and health literacy. The goal is to learn more so doctors can better support patients in us…

This observational study will interview 10 to 20 adults receiving chemotherapy as outpatients at a Turkish hospital. Researchers want to understand how patients perceive nursing care that is tailored to their individual needs, values, and lifestyle. The goal is to identify what m…

This study looks back at medical records of 2000 women with HER2-positive early breast cancer who still had cancer after initial treatment. Researchers want to see which follow-up drug regimen—trastuzumab plus pertuzumab or T-DM1—leads to better long-term outcomes. The goal is to…

This study will collect data from 500 Danish cancer patients who need repeat radiation therapy (reirradiation). Researchers will track side effects, tumor control, and survival to build a database that can guide safer treatment in the future. The goal is to help doctors decide wh…

This study will follow 75 women aged 18-42 with early-stage triple-negative breast cancer who are receiving chemotherapy plus immunotherapy before surgery. Researchers will measure hormone levels, track menstrual patterns, and use questionnaires to see how treatment affects ovari…

This study aims to find blood markers that can predict which cancer patients will develop chronic nerve pain from chemotherapy. Researchers will collect blood samples and perform neurological exams on 192 patients over 6 months. The goal is to use this information to personalize …

This study looks back at data from 201 people with triple-negative breast cancer who received chemotherapy or immunotherapy before surgery. The goal is to compare how often the cancer completely disappears after treatment and find out what factors influence success. This is an ob…

This study will test whether cancer patients receiving chemotherapy and radiation therapy can use wearable health devices, like fitness trackers, to monitor their heart rate and activity levels. Twenty adults will wear the device during treatment and for four weeks after, uploadi…

This study looks at whether an artificial intelligence (AI) tool can safely and accurately help breast cancer patients learn about their condition and treatment. About 35 adults with breast cancer will use the AI tool and answer surveys. The goal is to see if the tool is helpful …

This study will enroll 235 women with hormone receptor-positive, HER2-negative breast cancer who are taking abemaciclib after surgery. Researchers want to see if higher levels of the drug in the blood are linked to severe diarrhea, a common side effect. By understanding this link…

This study looks at whether tiny particles called exosomes, released by breast cancer cells, contain genetic material (microRNA) that can predict how well chemotherapy will work before surgery. Researchers will collect tumor tissue and blood samples from 60 women with breast canc…

This observational study will follow 300 women aged 45-55 with hormone receptor-positive breast cancer to see if changes in a hormone called AMH can predict when they will reach menopause. Researchers will collect blood samples at seven time points and track menstrual patterns. T…

This study will test an AI-powered tool that analyzes tumor samples to help doctors choose the best treatment for people with triple-negative breast cancer. The tool looks at immune cells in the tumor to predict how well chemotherapy might work. The goal is to see if the tool can…

This study checks if a short questionnaire called G8 can correctly identify frailty in people aged 70 and older with solid tumors. Researchers will compare the G8 results with a full geriatric assessment in 150 patients. The goal is to see if the G8 tool works well for Portuguese…

This study aims to create a simple tool (called a nomogram) that predicts the chance of breast cancer coming back in women with HR+/HER2- early-stage breast cancer. Researchers will look back at the records of 500 patients to find patterns that help personalize risk estimates. Th…

This study is testing a new web and mobile app called SHIELD, designed to support women with hormone receptor-positive breast cancer who are on long-term hormone therapy. The goal is to see if the app is easy to use and helpful for managing treatment. About 30 women will particip…

This study observes 400 adults with advanced HER2-negative breast cancer who have already received antibody-drug conjugates. Researchers will track how long patients stay cancer-free or alive after starting eribulin-based therapy. The goal is to understand real-world treatment ou…

This study looks for biological markers in tumor tissue and blood that may be linked to anxiety and depression in people with solid tumors. Researchers will combine psychological assessments with lab tests to better understand these emotional struggles. The goal is to improve ear…

This study looks at 150 breast cancer patients starting T-DXd, a drug that often causes nausea, vomiting, and weight loss. Researchers will measure blood levels of a hormone called GDF-15 before and during treatment to see if changes in GDF-15 are linked to these side effects. If…

This study will collect blood and swab samples from 160 adults with solid tumors who are about to start immunotherapy. The goal is to find a biological 'signature' that can predict which patients will develop severe immune-related side effects. If such a signature is found, it co…

This observational study looks at how having type 2 diabetes impacts quality of life in cancer patients receiving immunotherapy. Researchers will compare changes in well-being over six months between patients with and without diabetes. About 920 adults with solid tumors will fill…

This study will follow 81 people with early-stage, hormone-positive breast cancer who are at high risk of the cancer coming back. Researchers want to see how often patients take their prescribed CDK4/6 inhibitor pills (abemaciclib or ribociclib) alongside standard hormone therapy…

This study looks at how cancer patients view their doctor's compassion, communication, and professionalism when the doctor uses an electronic health record (EHR) during the visit. About 88 adults with cancer will watch videos or fill out questionnaires. The goal is to understand …

This study enrolls 275 people with advanced solid tumors to test a new approach: using a rapid, detailed analysis of each patient's tumor and immune system to guide treatment choices. The goal is to improve the success rate of immunotherapy, which currently helps only 20-30% of p…

This study will compare two different tissue expanders used in breast reconstruction after mastectomy in 80 women. Some participants will also receive radiation therapy, which is not typically recommended with these devices. Researchers will evaluate aesthetic outcomes, patient s…

This study looks at whether doing broad gene testing early, instead of later, helps find more effective treatments for people with advanced pancreatic, liver, or triple-negative breast cancer. About 360 adults with poor-prognosis cancers will be randomly assigned to early or stan…

This study will track gut microbiome changes in 12 women with hormone receptor-positive breast cancer starting Verzenio (abemaciclib) therapy. Participants will take either a resistant potato starch supplement or a placebo, and provide stool samples and symptom questionnaires rem…

This study aims to better understand psychiatric disorders, thinking problems, and treatment side effects in 2000 cancer patients and their close relatives. Researchers will compare those with and without mental health issues to find patterns and improve care. No new treatments a…

This study will test a new AI tool called BaiXiaoAi that helps cancer patients, their families, and their doctors stay connected. About 300 adults with cancer will join a special WeChat group where the AI answers questions and shares helpful information. The goal is to see if the…

This study will test a remote monitoring platform designed to help cancer patients who face barriers like language or lack of insurance. About 50 adults with cancer will use the platform at home to track symptoms and communicate with their care team. The goal is to see if the pla…

This study will test a new way to offer vaccines to vulnerable patients—those with chronic diseases or weakened immune systems—during hospital visits. Researchers will see if offering, prescribing, and giving vaccines in the hospital increases how many people get vaccinated. The …

This study follows 700 cancer patients who take blood thinners and are scheduled for surgery or medical procedures. Researchers will track how often major bleeding or clotting events occur within 30 days after the procedure. The goal is to see if current blood thinner management …

This study looks at stored tumor samples from 70 women with a common type of breast cancer (ER-positive, HER2-negative) who received hormone therapy. Researchers want to see if two specific proteins, p-AKT and p-S6, can help tell which cancers will respond to treatment and which …

This study looks at whether breast cancer's biology changes when it returns after treatment. Researchers will review medical records of 200 patients treated between 2015 and 2025. The goal is to see how often key markers differ between the first tumor and the recurrence, which co…

This study tests whether a 3.5-minute educational video shown before a doctor's visit helps cancer patients understand radiation therapy better than standard verbal instructions alone. One hundred patients scheduled for radiation will be randomly assigned to receive either the vi…

This study will check if people with metastatic breast or colon cancer have antibodies that might also attack the heart. Researchers will collect blood samples and ECGs from 196 participants over 12 months. The goal is to see if these antibodies raise the risk of dangerous heart …

This study follows 100 young cancer patients (ages 0-18) who freeze their ovarian tissue before treatment. Researchers want to see how safe the procedure is and how many go on to have a baby after transplanting the tissue back. The goal is to learn if this method effectively pres…

This study looks at whether audio recording a clinic visit helps advanced cancer patients remember what their doctor said and share it with family. About 200 patients at MD Anderson Cancer Center will be asked to record part of their visit and later report if it was useful. The g…